The MedTech Go-to-Market Playbook: From FDA Clearance to First Meetings

The hardest sale in MedTech isn't the clinical one — it's the one nobody budgets for. A team spends three years and $4–8M getting a device through FDA clearance, then launches the GTM motion with a webinar and a list of 600 hospital procurement contacts. Six months later, the pipeline is flat and the board is asking why the technology that just cleared the agency can't clear a CFO's calendar.

The gap is structural. MedTech GTM is treated as a marketing exercise when it's actually a precision-targeting problem with a short time-to-relevance window. This playbook covers the 90-day window after clearance and the outreach motion that turns it into meetings.

The 90-day window nobody plans for

FDA clearance creates a temporary asset: relevance. For roughly 90 days, your category is "new," your clinical evidence is current, and the buyers who track innovation are paying attention. After that window, you're another vendor in a crowded category competing on price.

Most MedTech teams miss this window because:

• The GTM team is hired after clearance, not before.
• Sales kickoff happens in month two, eating half the window.
• The first outreach is generic because the ICP wasn't pressure-tested against real buyers during the clinical trial.

The fix is to start the GTM motion 60 days before clearance — building the target list, validating the buyer map, and drafting the outreach sequence so the first touch goes out the week clearance is announced. This is the single highest-leverage move in MedTech GTM, and almost nobody does it.

Mapping the buying committee (it's bigger than you think)

A MedTech purchase decision at a health system involves 6–9 stakeholders, not the 2–3 most teams target (our healthcare buying committee guide covers each role and how to sequence them):

• Clinical champion (the physician who'll use the device)
• Department chair (controls the budget line)
• CMO / medical director (clinical risk sign-off)
• Value analysis committee (formal evaluation gate)
• Supply chain / procurement (contracting)
• IT / informatics (integration and data)
• Finance / CFO (ROI and capital approval)
• Patient safety / risk (liability review)
• Innovation committee (if the system has one — this is your entry point)

Your outreach can't address all nine. It has to sequence them: enter through the clinical champion or innovation committee, build the internal case with them, then arm them to carry it to value analysis and finance. Outreach that goes straight to procurement dies; procurement doesn't buy innovation, they negotiate the price of a decision someone else already made.

This is why the CMO messaging guide matters here — your clinical champion has to sell your device internally, and the artifacts you give them determine whether they can.

The targeting signals that matter post-clearance

After clearance, your target list should be built on signals that indicate willingness, not just fit:

• Innovation committee activity. Systems with active innovation programs are 3–4x more likely to evaluate a newly cleared device. Track published innovation charters and committee members.
• Recent capital event. A system that just issued bonds or closed a foundation grant has money in motion.
• Clinical trial site alumni. The investigators who ran your pivotal trial are your most credible internal champions at their home systems. This is the most underused list in MedTech.
• Departments with published growth plans. A cardiology department that just announced an expansion is buying, not just evaluating.
• Intent signals. Organizational research activity in your device category — see account propensity scoring for how to operationalize this.

Layering these signals gets you from 600 generic procurement contacts to 120 high-willingness clinical champions. That's the list that books.

The outreach sequence

The post-clearance sequence is different from a generic SaaS sequence because the stakes and the clinical credibility bar are higher:

• Touch 1 — the clearance + the clinical champion. Email to the clinical champion (not procurement). Names the clearance, cites the pivotal trial outcome in their specialty's terms, asks one clinical-practice question. No demo ask.
• Touch 2 — the investigator reference. Email, 5 days later. Names a trial investigator (ideally one they know) and the specific clinical outcome. This is your credibility anchor.
• Touch 3 — the internal sell-through kit. Email, 7 days later. A pre-built value analysis one-pager, an ROI model, and a patient safety summary — the artifacts your champion needs to get the device onto the value analysis committee agenda.
• Touch 4 — the peer deployment. LinkedIn or email, 10 days later. A named peer system that's live with the device and the clinical outcome. This is the message that moves a champion from interested to advocating.

The sequence runs long because MedTech buying committees don't move fast — but every touch is clinical-first. A vendor who leads with ROI before clinical credibility gets filtered out; a vendor who leads with clinical evidence and then equips the champion with the ROI model gets carried into the committee.

What goes wrong post-clearance

• Hiring the GTM team after clearance. You lose 60% of the relevance window before the first touch.
• Outreach to procurement. Procurement negotiates; they don't champion. You've entered at the end of the decision, not the beginning.
• Generic ICP targeting. "200+ bed hospitals" isn't a target list. It's a filter applied to a database. Our guide on how to sell to hospitals breaks down who actually buys inside one.
• No sell-through artifacts. Your champion has to build the internal case themselves, and they won't. Give them the kit.
• Ignoring the trial-site alumni list. The investigators who believe in your device already work at target systems. Not starting there is leaving your best list on the table.

The managed model advantage

For the full outbound and SDR playbook, see our MedTech lead generation guide.

MedTech GTM is the clearest case for a managed SDR motion because the bar is so high and the window so short. An in-house SDR hired post-clearance is still ramping when the relevance window closes. A managed team that's already trained on healthcare buyer committees, already running compliant outreach, and already equipped with the artifacts can launch the first touch the week clearance is announced.

The services stack — intent data for healthcare sales, AI-assisted research, continuous data remediation, and the sell-through kit — exists specifically so the 90-day window doesn't close before the pipeline opens.

What to do this week

1. If you're pre-clearance: start the GTM motion now. Build the target list, validate the buyer map, draft the sequence. The week of clearance is not the time to start.
2. If you're post-clearance: audit your current target list against the willingness signals above. If it's a bed-count filter, you're missing the window.
3. Build the sell-through kit — the one-pager, ROI model, and patient safety summary your champions need to carry your device into value analysis.
4. Activate your trial-site alumni list. Email the investigators. They're your best untapped pipeline.
5. Read the CMO messaging guide — your champions have to sell internally, and this is the playbook they'll use.

FDA clearance is a license to sell, not a guarantee of sales. The 90 days after it are when the pipeline is won or lost — and most teams lose them without realizing they were ever open. Book a demo if you want to see the post-clearance sequence running live.

Frequently asked questions

How do you sell into health systems after FDA clearance? You sell into health systems after FDA clearance by mapping clinical champions inside target IDNs, sequencing procurement and value-analysis committees, and leading with clinical evidence and ROI. The playbook shifts from a regulatory milestone to a commercial motion: identify the right buyers, build the clinical case, and start meetings before the competition does.

What's the biggest MedTech go-to-market mistake? The biggest MedTech go-to-market mistake is treating FDA clearance as the finish line. Clearance unlocks the right to sell — it doesn't create pipeline. Companies that wait for inbound interest lose 6–12 months of revenue while competitors with active SDR engines capture the limited pool of early-adoption health systems.

How fast should MedTech pipeline build after launch? MedTech pipeline should begin building in the first 7–14 days post-clearance. With dedicated healthcare SDRs and intent data, you can identify and sequence the 200–400 accounts most likely to adopt early, booking first meetings within weeks — not quarters.

Does MedTech outreach need to be HIPAA-compliant? Any outreach touching protected health information, clinical workflows, or patient-data contexts must be HIPAA-compliant. Even outreach to administrators is safer when healthcare-specialized SDRs operate within compliant sequencing and data-handling standards — it avoids procurement red flags later.